In the present retrospective study, we adopted an approach aimed at describing both the “quantity” and “quality” of immune response in early-stage HER2-positive breast cancer by exploring the characteristics of baseline BCR and TCR repertoires in the NeoALTTO and CALGB 40601 phase III neoadjuvant clinical trials. Here, BCR is linked to breast carcinoma.